May Han
Private Equity Investor chez Cure Ventures Management LP
Profil
May Han is currently a Partner at Cure Ventures Management LP since 2021.
Prior to this, she worked as a Director at Novartis AG from 2013 to 2021 and as a Director at AVEO Pharmaceuticals, Inc. from 2003 to 2012.
Dr. Han received her undergraduate degree from Peking University in 1990 and her doctorate degree from Yale University in 1996.
Postes actifs de May Han
| Sociétés | Poste | Début |
|---|---|---|
Cure Ventures Management LP
 Cure Ventures Management LP Investment ManagersFinance Cure Ventures Management LP (Cure Ventures) is a venture capital firm founded in 2021 by David R Fallace, Richard J Lim and Lou A Tartaglia. The firm is headquartered in Boston, Massachusetts. | Private Equity Investor | 01/09/2021 |
Anciens postes connus de May Han
| Sociétés | Poste | Fin |
|---|---|---|
| NOVARTIS AG | Directeur/Membre du Conseil | 30/09/2021 |
| AVEO PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 30/06/2012 |
Formation de May Han
| Peking University | Undergraduate Degree |
| Yale University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NOVARTIS AG | Health Technology |
| Entreprise privées | 2 |
|---|---|
Cure Ventures Management LP
Cure Ventures Management LP Investment ManagersFinance Cure Ventures Management LP (Cure Ventures) is a venture capital firm founded in 2021 by David R Fallace, Richard J Lim and Lou A Tartaglia. The firm is headquartered in Boston, Massachusetts. | Finance |
AVEO Pharmaceuticals, Inc.
 AVEO Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA. | Health Technology |
